Fig. 1.

Flow chart of patient inclusion. Of 2855 participants from the DD2 cohort, 24 were carriers of potentially functional GCK variants, defined as nonsense, frame-shift, or missense variants, and variants up to two nucleotides into intron/exon bounds with a frequency < 0.1% in GnomAD. Eight participants agreed to take part in a clinical examination, and five continued on to the treatment discontinuation trial. B = benign variant carrier, FPG = fasting plasma glucose, P/LP = pathogenic or likely pathogenic variant carrier, OGTT = oral glucose tolerance test, PG = plasma glucose, VUS=Variant of Uncertain Significance carrier. *One carrier of an LP variant was also a carrier of a VUS.